Search
Gadopentetic acid
go.drugbank.com/drugs/DB00789ApprovedInvestigational(From Martindale, The Extra Pharmacopoeia, 30th ed, p706) … A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs.
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. … [A34604] Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation.
Zapomeran
go.drugbank.com/drugs/DB21761Approved[L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell. … [L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585]
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnTideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. … It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.
Methotrimeprazine
go.drugbank.com/drugs/DB01403ApprovedIt has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDiazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A190372] Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. … [A190372] When administered intravenously, diazoxide can be used to treat hypertensive emergencies;[L44622] however, this specific form of diazoxide is no longer available in the US.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. … It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.